Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

被引：0

作者：

Yosipovitch, Gil ^{[1
]}

Staender, Sonja ^{[2
]}

Metz, Martin ^{[3
]}

Pink, Andrew E. ^{[4
]}

Silverberg, Jonathan, I ^{[5
]}

Sofen, Howard ^{[6
]}

Ahmed, Faiz ^{[7
]}

Noda, Aliene ^{[8
]}

Lopez, Zarif K. Jabbar ^{[8
]}

Piketty, Christophe ^{[8
]}

Kwatra, Shawn G. ^{[9
,10
]}

机构：

[1] Univ Miami, Miami Itch Ctr, Miller Sch Med, Miami, FL USA

[2] Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany

[3] Charite, Inst Allergol, Berlin, Germany

[4] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[5] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[6] UCLA, Sch Med, Dept Med Dermatol, Los Angeles, CA USA

[7] Galderma Labs, Dallas, TX USA

[8] Galderma R&D, Zug, Switzerland

[9] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD USA

[10] Univ Maryland, Maryland Itch Ctr, Sch Med, Baltimore, MD USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

efficacy; nemolizumab; prurigo nodularis; pruritus; safety; TRIAL;

D O I：

10.1093/bjd/ljae266.046

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

672

引用

页码：47 / 48

页数：2

共 50 条

[1] Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)
Staender, Sonja
Yosipovitch, Gil
Legat, Franz J.
Reich, Adam
Paul, Carle
Simon, Dagmar
Naldi, Luigi
Silverberg, Jonathan, I
Gharib, Rola
Fleischer, Alan
Laquer, Vivian T.
Ahmad, Faiz
Jabbar-Lopez, Zarif
Piketty, Christophe
Kwatra, Shawn G.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[2] Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis The OLYMPIA 1 Randomized Clinical Phase 3 Trial
Staender, Sonja
Yosipovitch, Gil
Legat, Franz J.
Reich, Adam
Paul, Carle
Simon, Dagmar
Naldi, Luigi
Metz, Martin
Tsianakas, Athanasios
Pink, Andrew
Fage, Simon
Micali, Giuseppe
Weisshaar, Elke
Sundaram, Hema
Metelitsa, Andrei
Augustin, Matthias
Wollenberg, Andreas
Homey, Bernhard
Fargnoli, Maria Concetta
Sofen, Howard
Korman, Neil J.
Skov, Lone
Chen, Xiaoxiao
Jabbar-Lopez, Zarif K.
Piketty, Christophe
Kwatra, Shawn G.
JAMA DERMATOLOGY, 2025, 161 (02) : 147 - 156
[3] Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (liberty-pn prime and prime2)
Yosipovitch, G.
Kwatra, S. G.
Mollanazar, N.
Staender, S.
Satoh, T.
Laws, E.
Mannent, L. P.
Mortensen, E.
Maloney, J.
Shi, G.
Bansal, A.
Martincova, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S111 - S111
[4] Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Yosipovitch, Gil
Kwatra, Shawn G.
Mollanazar, Nicholas
Staender, Sonja
Satoh, Takahiro
Laws, Elizabeth
Mannent, Leda P.
Mortensen, Eric
Maloney, Jennifer
Shi, Genming
Bansal, Ashish
Martincova, Renata
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[5] Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials
Bewley, A.
Thyssen, J. P.
Chiu, W. S.
Rojo, R.
Biswas, P.
Feeney, C.
DiBonaventura, M.
Misery, L.
Stander, S.
Cork, M.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E72 - E73
[6] Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis
Yosipovitch, Gil
de Bruin-Weller, Marjolein
Wiseman, Marni
Elberling, Jesper
Gutermuth, Jan
Pierce, Evangeline
Montmayeur, Sonia
Ding, Yuxin
Yang, Emily
Chisolm, Sarah
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB61 - AB61
[7] Dupilumab improves itch and skin lesions in North American patients with prurigo nodularis: a subset analysis of the pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Elmariah, Sarina B.
Mollanazar, Nicholas
Hong, H. Chi-ho
Walker, Kirsten
Butler, Daniel C.
Praestgaard, Amy
Zahn, Joseph
Wiggins, Simmi
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[8] Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
Silverberg, Jonathan, I
Wollenberg, Andreas
Legat, Franz J.
Laquer, Vivian T.
Ulianov, Liliana
Cheong, Soo Yeon
Ryzhkova, Anna
Piketty, Christophe
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[9] Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Yosipovitch, Gil
Kim, Brian S.
Kwatra, Shawn G.
Mollanazar, Nicholas K.
Stander, Sonja
Satoh, Takahiro
Mendes-Bastos, Pedro
Tsai, Tsen-Fang
Laws, Elizabeth
Nivens, Michael C.
Maloney, Jennifer
Shi, Genming
Bansal, Ashish
Dubost-Brama, Ariane
JAAD INTERNATIONAL, 2024, 16 : 163 - 174
[10] Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil
Bogan, Richard K.
Lee, Daniel O.
Buchfuhrer, Mark J.
Jaros, Mark J.
Kim, Richard
Shang, Gwendoline
ANNALS OF MEDICINE, 2015, 47 (03) : 269 - 277

← 1 2 3 4 5 →